Alivus Life Sciences Past Earnings Performance
Past criteria checks 2/6
Alivus Life Sciences has been growing earnings at an average annual rate of 7.9%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 4.3% per year. Alivus Life Sciences's return on equity is 16.7%, and it has net margins of 19.2%.
Key information
7.9%
Earnings growth rate
4.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 4.3% |
| Return on equity | 16.7% |
| Net Margin | 19.2% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Alivus Life Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 22,049 | 4,235 | 2,745 | 0 |
| 30 Jun 24 | 22,934 | 4,469 | 2,669 | 0 |
| 31 Mar 24 | 22,832 | 4,709 | 2,701 | 0 |
| 31 Dec 23 | 23,679 | 5,193 | 2,391 | 0 |
| 30 Sep 23 | 23,359 | 5,055 | 2,166 | 0 |
| 30 Jun 23 | 22,498 | 4,937 | 1,879 | 0 |
| 31 Mar 23 | 21,612 | 4,670 | 1,896 | 0 |
| 31 Dec 22 | 20,540 | 4,195 | 1,812 | 0 |
| 30 Sep 22 | 20,357 | 4,182 | 1,768 | 0 |
| 30 Jun 22 | 20,882 | 4,265 | 1,722 | 0 |
| 31 Mar 22 | 21,232 | 4,187 | 1,744 | 0 |
| 31 Dec 21 | 20,763 | 4,245 | 1,733 | 0 |
| 30 Sep 21 | 20,541 | 4,142 | 1,669 | 0 |
| 30 Jun 21 | 20,131 | 3,714 | 1,608 | 0 |
| 31 Mar 21 | 18,852 | 3,516 | 1,553 | 0 |
| 31 Mar 20 | 15,373 | 3,131 | 1,545 | 0 |
| 31 Mar 19 | 8,864 | 1,956 | 1,169 | 0 |
| 31 Mar 18 | 2 | -4 | 2 | 0 |
Quality Earnings: GLS has high quality earnings.
Growing Profit Margin: GLS's current net profit margins (19.2%) are lower than last year (21.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GLS's earnings have grown by 7.9% per year over the past 5 years.
Accelerating Growth: GLS's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: GLS had negative earnings growth (-16.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (20%).
Return on Equity
High ROE: GLS's Return on Equity (16.7%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 17:52 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Alivus Life Sciences Limited is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Saad Shaikh | BOB Capital Markets Ltd. |
| Neha Manpuria | BofA Global Research |
| Nitin Agarwal | DAM Capital Advisors |